Bone Biologics Corp
BBLG
Company Profile
Business description
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Contact
2 Burlington Woods Drive
Suite 100
BurlingtonMA01803
USAT: +1 781 552-4452
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
stocks
3 Warren Buffett stocks to avoid today
These are the most overvalued stocks in Berkshire Hathaway’s portfolio.
stocks
Should you invest in small caps?
With small capitalisation stocks gaining momentum, there are important considerations to determine whether they are right for your portfolio.
stocks
Strong second half anticipated for ASX mining play
A more focused business model should benefit the company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,079.20 | 17.70 | 0.20% |
| CAC 40 | 7,843.76 | 48.34 | 0.62% |
| DAX 40 | 23,624.08 | 89.25 | 0.38% |
| Dow JONES (US) | 45,947.32 | 173.96 | -0.38% |
| FTSE 100 | 9,261.39 | 47.41 | 0.51% |
| HKSE | 26,128.20 | 356.48 | -1.35% |
| NASDAQ | 22,384.70 | 113.16 | -0.50% |
| Nikkei 225 | 45,354.99 | 399.94 | -0.87% |
| NZX 50 Index | 13,111.73 | 42.06 | -0.32% |
| S&P 500 | 6,604.72 | 33.25 | -0.50% |
| S&P/ASX 200 | 8,787.70 | 13.20 | 0.15% |
| SSE Composite Index | 3,828.11 | 25.20 | -0.65% |